Tag: CAPLYTA
-
J&J’s CAPLYTA Meets Phase 3 Trial Goal in Bipolar Mania
Johnson & Johnson’s CAPLYTA met the primary endpoint in Phase 3 Study 451, producing a 4.8-point greater reduction in manic symptoms versus placebo and significant improvement from Day 3. Results from the second pivotal study remain under analysis.